Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Arrowhead Pharmaceuticals logo — Gene silencing platform targeting liver, lung, CNS, and meta...

Arrowhead Pharmaceuticals

Gene silencing platform targeting liver, lung, CNS, and metabolic diseases

Founded 2003 United States Pasadena, United States 773 employees IPO Total: $1.33B Biotechnology

General Information

Company Name Arrowhead Pharmaceuticals
Founded Year 2003
Location United States Pasadena, United States
Employees 773
Industries Biotechnology
Funding Stage IPO
Business Model Platform, B2B, B2B2C
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Arrowhead Pharmaceuticals. To contact Arrowhead Pharmaceuticals, visit arrowheadpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arrowhead Pharmaceuticals compare?

A PDF of Arrowhead Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arrowhead Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biotechnology company founded in 2003, specializing in a gene silencing platform that targets liver, lung, CNS, and metabolic diseases. The company's mission is to redefine medicine and provide innovative solutions for treating challenging illnesses.

By focusing on collaboration and innovation, Arrowhead Pharmaceuticals is adept at rapidly advancing drugs from discovery through to clinical stages. This capability suggests a strong pipeline potential and positions the company advantageously within the competitive biotech space.

The latest strategic financial move was a substantial $500 million Post IPO Equity investment led by Sixth Street on 01 August 2024. This injection of funds will likely enhance its R&D capabilities and accelerate its go-to-market strategies for pioneering treatments, presenting a compelling opportunity for investors looking to support transformative healthcare solutions.

Business keywords: Gene Silencing, Liver Diseases, Lung Diseases, CNS Diseases, Metabolic Diseases, Therapeutic Development, Hard-to-Treat Illnesses, Drug Discovery, Clinical Advancement, RNA Interference (RNAi), Pharmaceuticals, Medical Innovation, Healthcare Revolution, Collaborative Research

Services & Products

Gene Silencing
Drug Development using TRiM Platform
Clinical Trials
Scientific Research

Target Customers

Patients with Cardiovascular and Pulmonary Diseases Healthcare Providers Biotechnology Investors Scientific Research Community

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $500.00M 1
Sixth Street
01 Aug 2024
Post-IPO Equity $450.00M -
01 Jan 2024
Post-IPO Equity $266.80M -
01 Dec 2019
Post-IPO Equity $9.60M 1
Silence Therapeutics
01 Jan 2017
Private Placement VC $45.00M 4
RA Capital Management OrbiMed Perceptive Advisors
RA Capital Management, OrbiMed +2
01 Aug 2016
Private Placement VC $60.00M 1
RA Capital Management
RA Capital Management
01 Oct 2013
Spac IPO Undisclosed 1
Interactive Group
01 Jan 2004
Early VC $2.65M -
01 Oct 2003

Arrowhead Pharmaceuticals Alternatives & Competitors

View All Alternatives
Arrowhead Pharmaceuticals vs
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals

Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.

Post-IPO Equity
201-500 employees
Biotechnology, Health Care
Arrowhead Pharmaceuticals vs
BIORCHESTRA Co., Ltd.
BIORCHESTRA Co., Ltd. United States

We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift for neurod...

Series C
17 employees
Biopharma, Biotechnology
Arrowhead Pharmaceuticals vs
Aria Pharmaceuticals
Aria Pharmaceuticals United States

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel...

Series B
4 employees
AI, Big Data
View all alternatives

FAQ About Arrowhead Pharmaceuticals

Gene silencing platform targeting liver, lung, CNS, and metabolic diseases
Arrowhead Pharmaceuticals was founded in 2003.
Arrowhead Pharmaceuticals is headquartered in Pasadena, United States.
Arrowhead Pharmaceuticals operates in Biotechnology. Its work centres on Gene Silencing, Liver Diseases, Lung Diseases and CNS Diseases. Its customers include Patients with Cardiovascular and Pulmonary Diseases, Healthcare Providers and Biotechnology Investors.
Arrowhead Pharmaceuticals has a Platform, B2B and B2B2C business model. Its revenue comes from Licensing and Product Sales.
Arrowhead Pharmaceuticals has approximately 773 employees.
Arrowhead Pharmaceuticals has completed 8 funding rounds, raising a total of $1.33B. The latest funding stage is IPO.
Arrowhead Pharmaceuticals offers: Gene Silencing, Drug Development using TRiM Platform, Clinical Trials, Scientific Research.
Top alternatives and competitors to Arrowhead Pharmaceuticals include Dicerna Pharmaceuticals, BIORCHESTRA Co., Ltd., Aria Pharmaceuticals, Benitec Biopharma Inc., GENFIT. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arrowhead Pharmaceuticals and Dicerna Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arrowhead Pharmaceuticals, https://bouncewatch.com/company/arrowhead-pharmaceuticals, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout